Evidence map›Paper›PMID 33811169›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Less Is More-Ways to Move Forward for Improved Breast Cancer Risk Stratification.

Parisa Tehranifar, Ying Wei, Mary Beth Terry

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Parisa TehranifarDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, New York. mt146@cumc.columbia.edu pt140@columbia.edu yw2148@columbia.edu.ORCID 0000-0002-0605-3934
Ying WeiHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. mt146@cumc.columbia.edu pt140@columbia.edu yw2148@columbia.edu.
Mary Beth TerryDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, New York. mt146@cumc.columbia.edu pt140@columbia.edu yw2148@columbia.edu.
Columbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer risk models increasingly are including mammographic density (MD) and polygenic risk scores (PRS) to improve identification of higher-risk women who may benefit from genetic screening, earlier and supplemental breast screening, chemoprevention, and other targeted interventions. Here, we present additional considerations for improved clinical use of risk prediction models with MD, PRS, and questionnaire-based risk factors. These considerations include whether changing risk factor patterns, including MD, can improve risk prediction and management, and whether PRS could help inform breast cancer screening without MD measures and prior to the age at initiation of population-based mammography. We further argue that it may be time to reconsider issues around breast cancer risk models that may warrant a more comprehensive head-to-head comparison with other methods for risk factor assessment and risk prediction, including emerging artificial intelligence methods. With the increasing recognition of limitations of any single mathematical model, no matter how simplified, we are at an important juncture for consideration of these different approaches for improved risk stratification in geographically and ethnically diverse populations.

Indexed as

Breast DensityBreast NeoplasmsArtificial IntelligenceFemaleHumansMammographyPolymorphism, Single NucleotideRisk AssessmentRisk FactorsSurveys and Questionnaires

Identifiers

PMID33811169
OpenAlexW3148221891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.